BioCentury
ARTICLE | Politics & Policy

Massachusetts compromises on weaker Medicaid drug price disclosures

July 22, 2019 8:49 PM UTC

Responding to a biopharma industry lobbying campaign, the Massachusetts legislature has dialed back drug price and cost disclosure requirements. The requirements are part of provisions in the state budget that create a new Medicaid supplemental rebate for high-priced drugs.

MassBio, a trade association, led an effort that prompted the House to dramatically reduce disclosure requirements associated with negotiating supplemental rebates, but failed to win similar concessions in the Senate (see "Massachusetts House Dilutes Medicaid Drug Pricing Bill" and "Massachusetts Senate Rejects Budget Amendment Curbing Drug Pricing Requirements"). ...